Matthew Gall, an industry veteran, has joined iTeos Therapeutics Inc as chief financial officer to help advance the company’s early-stage immuno-oncology portfolio. He joins from Sarepta Therapeutics Inc where he led that company’s recent licencing deal with Roche for a gene therapy for Duchenne muscular dystrophy. Mr Gall also held management positions at Celgene Corp (now part of Bristol-Myers Squibb) and Gilead Sciences Inc. He earned a Master of Business Administration from the University of Chicago Booth School of Business, US.
Also joining iTeos is Yvonne McGrath to lead R&D, and Philippe Brantegem to manage human resources. Dr McGrath previously worked at Complix NV as chief scientific officer. She holds a PhD from the University of Wales, College of Medicine, UK.
Mr Brantegem has worked in human resources for multiple pharma companies including Merck Sharp & Dohme.
iTeos Therapeutics announced the appointments on 9 June 2020.
Copyright 2020 Evernow Publishing Ltd